The importance of drug adverse effects compared with seizure control for people with epilepsy: A discrete choice experiment

PharmacoEconomics

Volumn 23, Issue 11, 2005, Pages 1167-1181

  Lloyd, Andrew ^a   McIntosh, Emma ^b   Price, Martin ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UBC ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ADULT; ALOPECIA; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE CONTROL; DRUG COST; DRUG INDUCED DISEASE; EPILEPSY; FEMALE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; NAUSEA; PRIORITY JOURNAL; RASH; STEVENS JOHNSON SYNDROME; WEIGHT GAIN;

ADULT; ANTICONVULSANTS; DECISION MAKING; EPILEPSY; FEES, PHARMACEUTICAL; FEMALE; HUMANS; MALE; QUESTIONNAIRES; SEIZURES; SOCIOECONOMIC FACTORS;

EID: 27744563315     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523110-00008     Document Type: Article

References (45)

1. Feely M. Drug treatment of epilepsy. BMJ 1999; 318: 106-9
2. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995; 36 Suppl. 2: S13-26
3. Swann AC. Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 2001; 62 Suppl. 14: 16-21
4. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993; 43: 2284-91
5. Mercke Y, Sheng H, Khan T, et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12 (1): 35-42
6. Strakowski SM, DelBello MP, Adler CM. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 2001; 15 (9): 701-18
7. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 2000; 41 Suppl. 2: S42-52
8. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res 2001; 47: 155-74
9. Coulter A, Entwistle V, Gilbert D. Sharing decisions with patients: is the information good enough? BMJ 1999; 318: 318-22
10. Holmes-Rovner M, Llewellyn-Thomas H, Entwistle V, et al. Patient choice modules for summaries of clinical effectiveness: a proposal. BMJ 2001; 322: 664-7
11. van der Pol M, Cairns JA. Estimating time preferences for health using discrete choice experiments. Soc Sci Med 2001; 52: 1459-70
12. van der Pol M, Cairns J. Establishing patient preferences for blood transfusion support: an application of conjoint analysis. J Health Serv Res Policy 1998; 3 (2): 70-6
13. Ratcliffe J, Buxton M. Patients' preferences regarding the process and outcomes of life saving technology: an application of conjoint analysis to liver transplantation. Int J Technol Assess Health Care 1999; 15: 340-51
14. Bryan S, Buxton M, Sheldon R, et al. Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences. Health Econ 1998; 7 (7): 595-603
15. Ryan M, Scott DA, Reeves C. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001; 5 (5): 1-186
16. Huber J, Zwerina K. The importance of utility balance in efficient choice designs. J Mark Res 1996; 33: 307-17
17. Baker GA, Jacoby A, Buck D, et al. Quality of life of people with epilepsy: a European study. Epilepsia 1997; 38: 353-62
18. Berto P. Quality of life in patients with epilepsy and impact of treatments. Pharmacoeconomics 2002; 20 (15): 1039-59
19. GlaxoSmithKline. Lamictal monograph, GlaxoSmithKline, 2001 [online]. Available from URL: http://us.gsk.com/products/assets/us_lamictal.pdf [Accessed 2005 Sep 15]
20. Hart YM, Shorvon SD. The nature of epilepsy in the general population II: medical care. Epilepsy Res 1995; 21: 51-8
21. Novartis Pharmaceuticals. Tegretol® (carbamazepine) prescribing information, Novartis Pharmaceuticals, 1999 [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf [Accessed 2005 Sep 15]
22. Froberg DG, Kane RL. Methodology for measuring health-state preferences: I. measurement strategies. J Clin Epidemiol 1989; 42: 345-54
23. Ryan M. Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilisation. Soc Sci Med 1999 Feb; 48 (4): 535-46
24. Bradley M. User's manual for SPEED v 2.1 The Hague: Hague Consulting Group, 1991
25. Gigerenzer G. Reckoning with risk: learning to live with uncertainty. London: Penguin Books, 2002
26. Slovic P, editor. The perception of risk. London: Earthscan Publications Ltd, 2000
27. Entwistle V, Watt I, Davis H, et al. Developing information materials to present the findings of technology assessments to consumers. Int J Technol Assess Health Care 1998; 14 (1): 47-70
28. Bennet P, Calman K. Risk communication and public health. Oxford, UK: Oxford University Press, 1999
29. Gigerenzer G, Hoffrage U. How to improve Bayesian reasoning without instructions: frequency formats. Psychol Rev 1995; 98: 506-28
30. Reyna V, Brainerd C. Fuzzy-trace theory and framing effects in choice: gist extraction, truncation and conversion. J Behav Decis Making 1991; 4: 249-62
31. Reyna V, Brainerd C. Fuzzy-trace theory: an interim synthesis: learning and individual differences. Learn Individ Differ 1995; 7: 1-75
32. Reyna V, Lloyd F, Brainerd C. Memory, development and rationality: an integrative theory of judgment and decision-making. In: Schneider S, Shanteau J, editors. Emerging perspectives in judgment and decision making. Mahwah (NJ): Erlbaum, 2001
33. Green W. LIMDEP Version 8, Users Manual. Econometric Software Inc, 1998
34. Roe B, Boyle KJ, Teisl MF. Using conjoint analysis to derive estimates of compensating variation. J Environ Econ Manage 1996; 31: 145-9
35. Manski CF. The structure of random utility models. Theory Decis 1977; 8: 229-54
36. Hanemann WM. Welfare evaluations in contingent valuation experiments with discrete responses. Am J Agric Econ 1984; 66: 332-41
37. Font AR. Mass tourism and the demand for protected natural areas: a travel cost approach. J Environ Econ Manage 2000; 39: 97-116
38. Unutzer J, Katon WJ, Russo J, et al. Willingness to pay for depression treatment in primary care. Psychiatr Serv 2003 Mar; 54 (3): 340-5
39. Lenert LA. Use of willingness to pay to study values for pharmacotherapies for migraine headache. Pharmacoeconomics 2002; 20 (11): 739-47
40. Jacobs RJ, Moleski RJ, Meyerhoff AS. Valuation of symptomatic hepatitis A in adults: estimates based on time trade-off and willingness-to-pay measurement. Med Care 2003 Feb; 41 (2): 299-308
41. Stavem K. Willingness to pay: a feasible method for assessing treatment benefits in epilepsy? Seizure 1999; 8: 14-9
42. Jacoby A, Snape D, Baker GA. Epilepsy and social identity: the stigma of a chronic neurological disorder. Lancet Neurol 2005; 4: 171-8
43. Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998; 39: 776-86
44. Remak E, Hutton J, Peeters K, et al. Estimated impact of seizure frequency on survival in epilepsy. Association of British Neurologists Spring Scientific Meeting April 2-4, 2003; Cardiff, Wales, UK
45. British Epilepsy Association. The treatment of epilepsy: a patient's viewpoint. Leeds: British Epilepsy Association, 1996.